Publications

Fred Hutchinson CTD² researchers identified novel therapeutic targets for precision oncology using high-throughput functional phenotyping with siRNA and drug libraries in primary patient derived head and neck cancer cells.

Expression analysis reveals pan-cancer and tumor-specific MYC-associated pathways. Integrating these analysis results with the TCGA dataset could provide insights in understanding MYC-driven cancers and identify novel markers and therapeutic approaches for cancer treatments.

An automated decision tree genetic abnormalities analyses is used to stratify acute myeloid leukemia patients according to the European Leukemia Network guidelines.

UTMDACC developed a functional genomic platform used to annotate gene amplifications, point mutations, indels, and gene fusions of cancer variants. This data is accessible through a user-friendly, interactive open-access web portal, FASMIC (Functional Annotation of Somatic Mutations in Cancer).

CTD² scientists at the University of Texas MD Anderson Cancer Center demonstrated inhibition of bromodomain-containing four induced homologous recombination deficiencies. This inhibition resensitizes cells with acquired resistance to PARP inhibitors.

CTD² scientists at Emory University developed a high-throughput time-resolved fluorescence resonance energy transfer assay to discover small-molecule inhibitors of receptor binding protein, NSD3 protein-protein interactions.

Review of methods with a focus on chemical-genetic screens used in the identification of the mechanisms of action of small molecules.